What Fueled The Previous Growth In The Patient Controlled Injectors Market?
The patient controlled injectors market has seen considerable growth due to a variety of factors.
• The patient-controlled injectors market has grown rapidly in recent years. It is set to rise from $4.51 billion in 2024 to $5.1 billion in 2025, at a compound annual growth rate (CAGR) of 13.1%.
This growth is driven by the rise of home healthcare, expanding healthcare infrastructure, increasing cases of diabetes, the growing prevalence of infectious diseases, and a focus on personalized medicine.
What Is The Expected Growth In The Patient Controlled Injectors Market Size Evolve over the Forecast Period?
The patient controlled injectors market is expected to maintain its strong growth trajectory in upcoming years.
• The patient-controlled injectors market is expected to reach $8.25 billion by 2029, growing at a CAGR of 12.8%.
This growth is due to the aging population, rising chronic disease incidence, increased cancer cases, and autoimmune disorders. Key trends include technological advancements, AI integration, telemedicine, wearable devices, and minimally invasive procedures.
What Main Forces Are Fueling Expansion In The Patient Controlled Injectors Market?
The patient-controlled injectors market is anticipated to expand due to the rising occurrence of chronic diseases. These are prolonged health issues that typically persist three months or more and could progressively deteriorate. As the elderly population expands, the obesity crisis escalates, socioeconomic aspects shift, and exposure to harmful elements in the environment increases, chronic illnesses are becoming more common. Patient-controlled injectors empower individuals to manage their medications accurately, effortlessly, and in line with their treatment schedules. The National Center for Biotechnology Information (NCBI), a U.S. medical library, reported in January 2023 that the count of individuals aged 50 and older, suffering from one or multiple chronic diseases, is predicted to surge by 99.5% by 2050, escalating from 71.52 million in 2020 to 142.66 million. Thus, the escalating frequency of chronic diseases is expected to stimulate the expansion of the patient-controlled injectors market.
What Are The Primary Segments In The Global Patient Controlled Injectors Market?
The patient controlled injectors market covered in this report is segmented –
1) By Product: Electronic Wearable Injector, Mechanical Wearable Injector, Infusion Pumps
2) By Application: Cancer Treatment, Auto-Immune Treatment, Blood Disorder Treatment, Other Application
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies
Subsegments:
1) By Electronic Wearable Injector: Pre-Filled Electronic Wearable Injectors, Programmable Electronic Wearable Injectors, Smart Electronic Wearable Injectors, Rechargeable Electronic Wearable Injectors, Bluetooth-Enabled Electronic Wearable Injectors, Disposable Electronic Wearable Injectors
2) By Mechanical Wearable Injector: Spring-Loaded Mechanical Wearable Injectors, Piston-Based Mechanical Wearable Injectors, Auto-Injectors (Mechanical), Manual Mechanical Wearable Injectors, Disposable Mechanical Wearable Injectors
3) By Infusion Pumps: Disposable Infusion Pumps, Programmable Infusion Pumps, Insulin Infusion Pumps, Syringe Infusion Pumps, Ambulatory Infusion Pumps, Large Volume Infusion Pumps, Implantable Infusion Pumps
Pre-Book The Patient Controlled Injectors Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Patient Controlled Injectors Market?
Major businesses in the patient-controlled injectors market are paving the way by creating cutting-edge products including ready-to-use syringes, developed to cater to consumer needs more efficiently. Such syringes come prefilled and sterilized with a fixed dosage of medicine, thus doing away with the need for manual medication preparation and lowering the chances of contamination or dosage errors. For instance, in October 2022, Ypsomed AG, a medical equipment producer based in Switzerland, unveiled a novel autoinjector platform devised for liquid pharmaceuticals, this platform can hold between 1.5 and 5.5 ml of medicine. This ground-breaking tool has an ergonomic design for easy user handling, and guarantees patient comfort during the injection procedure. The device has in-built safety measures to avoid unintentional needle pricks and it provides the user with both visual and audible assurances when the delivery of the medication is successful. Additionally, this autoinjector can handle a variety of viscosity levels, rendering it adaptable for different therapeutic uses.
Who Are the Key Players In The Patient Controlled Injectors Market?
Major companies operating in the patient controlled injectors market are:
• Medtronic plc
• Becton Dickinson and Company
• West Pharmaceutical Services
• SCHOTT AG
• Gerresheimer AG
• Phillips-Medisize
• Vetter Pharma-Fertigung GmbH & Co. KG
• Stevanato Group
• Ypsomed AG
• Nemera
• B. Braun Melsungen AG
• Elcam Medical
• Owen Mumford
• Bespak
• Unilife Corporation
• Crossject
• SHL Group
• AptarGroup Inc.
• Credence MedSystems
• Weibel CDS AG
• Sorrel Medical
What Is The Most Dominant Region In The Patient Controlled Injectors Market?
North America was the largest region in the patient controlled injectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient controlled injectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
